Seeking Alpha

More on Novartis (NVS +1.7%) Q2: net income flat at $2.7B, with revenues slipping partly because...

More on Novartis (NVS +1.7%) Q2: net income flat at $2.7B, with revenues slipping partly because of patent expirations and the strength of the dollar. However, rising sales of new drugs, including Gilenya for multiple sclerosis and Afinitor for cancer, help offset the expirations. "Our pipeline is delivering," says CEO Joe Jimenez.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)